Strong sales and earnings propelled Genzyme Corp.'s second-quarter results past estimates and led the company to forecast continued growth that would offset any dilution related to its merger with ILEX Oncology Inc. (BioWorld Today)

Strong sales and earnings propelled Genzyme Corp.'s second-quarter results past estimates and led the company to forecast continued growth that would offset any dilution related to its merger with ILEX Oncology Inc. (BioWorld Today)